Clin2
NCT07147946Possibly a fitNot yet recruiting

Inhaled study drug for moderate-to-severe COPD

Chronic Obstructive Pulmonary Disease

Part of Lungs & breathing clinical trials.

This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe COPD. The goal is to see if it can help improve breathing and reduce flare-ups.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
666 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • Between 40 and 80 years old
  • Have a diagnosis of moderate-to-severe COPD
  • Have smoked for at least 10 pack-years (e.g., 1 pack a day for 10 years)
  • No COPD flare-up or hospital stay for COPD in the last 3 months
  • Can use a nebulizer and perform lung function tests
  • Not pregnant, breastfeeding, or planning pregnancy during the study
  • No other serious lung diseases or recent infections

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07464587Not yet recruiting· Phase 3
Study of Inhaled TQC3721 for Moderate-to-Severe COPD

This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It aims to see if the drug can improve lung function and symptoms. For some participants, the trial is available to those who have not been in a previous TQC3721 study.

Bozhou, Anhui
NCT07633314Not yet recruiting· Phase 2
New COPD Inhaler Treatment Comparison Study

This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.

Yulin, Guangxi
NCT07349524Recruiting· Phase 2
A study of an oral tablet for COPD

This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.

Guangzhou, Guangdong
NCT06829784Recruiting· Phase 3
Study of TQC2731 for severe asthma

This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.

Bozhou, Anhui
NCT07107256Recruiting· Phase 3
Study of TQC2731 for chronic sinusitis with nasal polyps

This trial tests an injectable drug called TQC2731 for people with chronic sinusitis and nasal polyps that haven't been controlled well enough by standard treatments like steroid sprays or surgery. The goal is to see if it helps reduce nasal congestion, improve sense of smell, and shrink polyps.

Fuyang, Anhui
NCT07640451Recruiting· Phase 2
HRS-9821 inhalation treatment for moderate to severe COPD

This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.

Shanghai, Shanghai Municipality

Hear when a new Chronic Obstructive Pulmonary Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.